Search

Figure S3. Correlation of fasting and intra-operative glucose levels with circulating chemerin in T2D. a Correlation of circulating chemerin levels with fasting glucose levels (r = −0.149, p = 0.53, n = 21). b Correlation of circulating chemerin levels with OP glucose (r = −0.025, p = 0.92, n = 21). (PDF 44 kb)

Figure S2. Correlation of fasting and intra-operative glucose levels with circulating chemerin in controls. a Correlation of circulating chemerin levels with fasting glucose levels (r = 0.216, p = 0.034, n = 17). b Correlation of circulating chemerin levels with OP glucose (r = 0.549, p = 0.023, n = 17). (PDF 44 kb)

Table S1: Inclusion and exclusion criteria for clinical studies. Table S2: Primer sequences and NCBI accession numbers. Table S3: Characterisitcs of matched subgroups. Table S4: Indications for open abdominal surgery. Table S5: Correlation of chemerin with clinical and paraclinical parameters in the first study cohort. Table S6: Correlation of chemerin with clinical and paraclinical parameters in second cohort.

Figure S1. Characterisation of the murine HFD model. a Development of body weight over 12 weeks of high-fat feeding. HFD mice gained significantly more body weight (n = 15/group). b Baseline plasma glucose levels were significantly higher in HFD-fed mice after 12 weeks compared with CD-fed mice (p = 0.01, n = 6). c Intra-peritoneal glucose tolerance test (ipGTT) showed no significant difference in glucose tolerance after 4 weeks of HFD (n = 4 or 5). d Area under the curve (AUC) was not significantly different for ipGTT between HFD- and CD-fed mice after 4 weeks of feeding (p = 0.286; n = 4 or 5). e HFD-fed mice had decreased glucose tolerance in ipGTT after 8 weeks of feeding (p = 0.04; n = 5). f Area under the curve (AUC) was significantly higher in HFD-fed mice compared with CD-fed mice after 8 weeks of feeding (p = 0.008, n = 5). (PDF 47 kb)